BOSTON, July 9, 2015 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced expanded
services and capabilities in model-based drug development (MBDD)
through their Quantitative Clinical Development (QCD) group.
The PAREXEL QCD team also offers leadership in all strategic and
quantitative aspects of clinical pharmacology for biopharmaceutical
companies to help expedite drug development, minimize risk, and
support regulatory approval processes.
Leveraging mathematical models for a quantitative analysis of
the relationship between drugs, disease and patients, modeling and
simulation can predict a drug's benefits and adverse effects in a
patient population prior to conducting a clinical trial. MBDD can
improve the efficiency of clinical development by providing
quantitative justification for trial design, dose selection, and
decisions during trial execution. In addition, quantitative
clinical pharmacology throughout the lifecycle of a drug candidate
supports high quality regulatory packages to help secure regulatory
approval.
"The biopharmaceutical landscape continues to show dramatic
change, putting companies under increasing pressure to deliver on
their pipeline, to identify more effective means of picking the
'winners' and efficiently developing these medicines under
financial constraints. In addition, regulatory authorities
around the world have increasingly accepted model-based techniques
as a standard component of new drug applications," said
Frank Hoke, PhD, Vice President of
QCD, PAREXEL. "Our goal is to reduce risk along the drug
development continuum – for drug developers and for patients –
while helping companies make sound investment decisions and
accelerating their drug's journey to market."
PAREXEL's Quantitative Clinical Development, one of the largest
groups in the industry providing modeling and simulation, is led by
Dr. Hoke and supported by a dedicated team of more than 30
scientists with an aggregate of 400-plus years of combined clinical
development experience. Dr. Hoke and a number of colleagues
joined PAREXEL from GlaxoSmithKline's Clinical Pharmacology
Modeling and Simulation department.
For more information about PAREXEL's QCD modeling and simulation
and quantitative clinical pharmacology services, visit
PAREXEL.com/solutions/clinical-research/quantitative-clinical-development.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of expertise-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics, Inc. provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston,
Massachusetts, PAREXEL operates in 80 locations in 51
countries around the world, and had approximately 17,440 employees
in the third quarter. For more information about PAREXEL
International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates. All other trademarks are the property of their
respective owners.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the
Company's ability to win new business, manage growth and costs, and
attract and retain employees; the Company's ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisitions of ClinIntel Limited and Quantum
Solutions India, or enter into new lines of business; the impact on
the Company's business of government regulation of the drug,
medical device and biotechnology industry; consolidation within the
pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant
liability to clients and third parties; the potential adverse
impact of health care reform; and the effects of foreign currency
exchange rate fluctuations and other international economic,
political, and other risks. Such factors and others are
discussed more fully in the section entitled "Risk Factors" of the
Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2015 as filed with the
Securities and Exchange Commission on May 1,
2015, which "Risk Factors" discussion is incorporated by
reference in this press release. The Company specifically
disclaims any obligation to update these forward-looking statements
in the future. These forward-looking statements should not be
relied upon as representing the Company's estimates or views as of
any date subsequent to the date of this press release.
Contacts:
Diana Martin, PAREXEL
International
Tel: +1
781-434-5516
Email:
Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
Matthew Briggs, PAN
Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-expands-model-based-drug-development-offering-300110476.html
SOURCE PAREXEL International Corporation